Extended Treatment in Metastatic Breast Cancer With Eribulin
EXTER
Long-term Eribulin Treatment in Metastatic Breast Cancer: A Multicenter, Case-study Analysis
1 other identifier
observational
45
1 country
21
Brief Summary
Decision-making for treatment of metastatic breast cancer after the second line of chemotherapy was limited by the lack of established predictive factors of benefit for further chemotherapy regimens. Eribulin has emerged as the only single agent demonstrating an overall survival improvement in the third-line setting or beyond. The purpose of this study was to define the clinical profile of metastatic breast cancer participants achieving long-term benefit from chemotherapy with eribulin in the third-line setting or beyond.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Nov 2013
Shorter than P25 for all trials
21 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
November 1, 2013
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 1, 2014
CompletedStudy Completion
Last participant's last visit for all outcomes
June 1, 2014
CompletedFirst Submitted
Initial submission to the registry
May 10, 2016
CompletedFirst Posted
Study publicly available on registry
May 11, 2016
CompletedJuly 24, 2023
May 1, 2016
7 months
May 10, 2016
July 21, 2023
Conditions
Keywords
Outcome Measures
Primary Outcomes (5)
Overall survival
up to 7 months
Progression free survival (PFS)
up to 7 months
Objective response rate
up to 7 months
Time to response
up to 7 months
Post progression survival
up to 7 months
Secondary Outcomes (1)
Number of participants with adverse events/serious adverse events/toxic deaths as a measure of safety
up to 7 months
Study Arms (1)
Participants treated with eribulin for at least 7 months
Eligibility Criteria
Participants with Advanced or Metastatic Breast Cancer on Eribulin for at least 7 months
You may qualify if:
- Participants with Advanced or Metastatic Breast Cancer on Eribulin for at least 7 months
You may not qualify if:
- Lack of accessible clinical records
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Eisai Limitedlead
Study Sites (21)
Unknown Facility
Santiago de Compostela, A Coruña, Spain
Unknown Facility
Las Palmas de Gran Canarias, Gran Canaria, Spain
Unknown Facility
San Sebastián, Guipuzcoa, Spain
Unknown Facility
Barbastro, Huesca, Spain
Unknown Facility
Alcorcón, Madrid, Spain
Unknown Facility
Aravaca, Madrid, Spain
Unknown Facility
Pozuelo de Alarcón, Madrid, Spain
Unknown Facility
Pamplona, Navarre, Spain
Unknown Facility
Bilbao, Vizcaya, Spain
Unknown Facility
Badajoz, Spain
Unknown Facility
Cáceres, Spain
Unknown Facility
Jaén, Spain
Unknown Facility
Lleida, Spain
Unknown Facility
Madrid, Spain
Unknown Facility
Málaga, Spain
Unknown Facility
Murcia, Spain
Unknown Facility
Ourense, Spain
Unknown Facility
Salamanca, Spain
Unknown Facility
Seville, Spain
Unknown Facility
Valencia, Spain
Unknown Facility
Zaragoza, Spain
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
May 10, 2016
First Posted
May 11, 2016
Study Start
November 1, 2013
Primary Completion
June 1, 2014
Study Completion
June 1, 2014
Last Updated
July 24, 2023
Record last verified: 2016-05